Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Fletcher

Showing results (311-320 of 342) with videos related to

Pageof 35
Sort By:
The Journal of Pathology|January 17, 2002
Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study GroupGiovanni Tallini, Howard Dorfman, Peter Brys, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomasJohn V Heymach, Jayesh Desai, Judith Manola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorMichael C Heinrich, Robert G Maki, Christopher L Corless, et al.
The American Journal of Pathology|March 15, 2013
R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformationsKyle C Kurek, Twinkal C Pansuriya, Maayke A J H van Ruler, et al.
Cancer|February 21, 2018
Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology GroupLisa A Teot, Michaela Schneider, Aaron R Thorner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Archives of Pathology & Laboratory Medicine|April 7, 2010
Protocol for the examination of specimens from patients with tumors of soft tissueBrian P Rubin, Kumarasen Cooper, Christopher D M Fletcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2011
Aberrant AKT activation drives well-differentiated liposarcomaAlejandro Gutierrez, Eric L Snyder, Adrian Marino-Enriquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Pageof 35

Showing results (311-320 of 342) with videos related to

Sort By:
Pageof 35
The Journal of Pathology|January 17, 2002
Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study GroupGiovanni Tallini, Howard Dorfman, Peter Brys, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomasJohn V Heymach, Jayesh Desai, Judith Manola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorMichael C Heinrich, Robert G Maki, Christopher L Corless, et al.
The American Journal of Pathology|March 15, 2013
R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformationsKyle C Kurek, Twinkal C Pansuriya, Maayke A J H van Ruler, et al.
Cancer|February 21, 2018
Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology GroupLisa A Teot, Michaela Schneider, Aaron R Thorner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Archives of Pathology & Laboratory Medicine|April 7, 2010
Protocol for the examination of specimens from patients with tumors of soft tissueBrian P Rubin, Kumarasen Cooper, Christopher D M Fletcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2011
Aberrant AKT activation drives well-differentiated liposarcomaAlejandro Gutierrez, Eric L Snyder, Adrian Marino-Enriquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Pageof 35